John Fasig Iii, MD | |
5301 Virginia Way, Suite 300, Brentwood, TN 37027-7541 | |
(615) 221-4474 | |
(615) 234-3774 |
Full Name | John Fasig Iii |
---|---|
Gender | Male |
Speciality | Pathology |
Experience | 21 Years |
Location | 5301 Virginia Way, Brentwood, Tennessee |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1104973080 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 43243 (Tennessee) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Tristar Centennial Medical Center | Nashville, TN | Hospital |
Baptist Memorial Hospital | Memphis, TN | Hospital |
Baptist Memorial Hospital Golden Triangle Inc | Columbus, MS | Hospital |
Greenview Regional Hospital | Bowling green, KY | Hospital |
Poplar Bluff Regional Medical Center | Poplar bluff, MO | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Associated Pathologists Llc | 0648167544 | 103 |
Associated Pathologists Llc | 0648167544 | 103 |
Associated Pathologists Llc | 0648167544 | 103 |
Associated Pathologists Llc | 0648167544 | 103 |
News Archive
Today's early morning highlights from the major news organizations include news on congressional package to payroll taxes and stop a Medicare payment cut and analysis of President Barack Obama's budget.
Researchers at Moffitt Cancer Center in Tampa, Fla., have found - contrary to previous studies linking inferior outcomes in patients with gastrointestinal malignancies to higher body mass index (BMI) - that in their study of BMI and negative outcomes, there was no such link. They concluded that BMI was not associated with either surgical complications or esophageal cancer patient survival.
Vertex Pharmaceuticals Incorporated today announced plans to enroll an additional treatment arm as part of its ongoing Phase 2 clinical trial evaluating 12-week regimens of Vertex's lead investigational hepatitis C virus (HCV) protease inhibitor, telaprevir, in combination with its lead investigational HCV polymerase inhibitor, VX-222.
Infants born to women with Inflammatory Bowel Disease (IBD) are no more likely to develop congenital malformations than infants born to healthy mothers, according to a study presented at the 69th Annual Scientific Meeting of the American College of Gastroenterology.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced the publication of new data in the journal Nature Biotechnology by Alnylam scientists and collaborators from Tekmira Pharmaceuticals Corporation, AlCana Technologies, Inc., and The University of British Columbia (UBC). The new study employed a rational design approach for the discovery of novel lipids that can be incorporated into lipid nanoparticles (LNPs) for systemic delivery of RNAi therapeutics.
› Verified 7 days ago
Entity Name | Associated Pathologists Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1003863580 PECOS PAC ID: 0648167544 Enrollment ID: O20040304000200 |
News Archive
Today's early morning highlights from the major news organizations include news on congressional package to payroll taxes and stop a Medicare payment cut and analysis of President Barack Obama's budget.
Researchers at Moffitt Cancer Center in Tampa, Fla., have found - contrary to previous studies linking inferior outcomes in patients with gastrointestinal malignancies to higher body mass index (BMI) - that in their study of BMI and negative outcomes, there was no such link. They concluded that BMI was not associated with either surgical complications or esophageal cancer patient survival.
Vertex Pharmaceuticals Incorporated today announced plans to enroll an additional treatment arm as part of its ongoing Phase 2 clinical trial evaluating 12-week regimens of Vertex's lead investigational hepatitis C virus (HCV) protease inhibitor, telaprevir, in combination with its lead investigational HCV polymerase inhibitor, VX-222.
Infants born to women with Inflammatory Bowel Disease (IBD) are no more likely to develop congenital malformations than infants born to healthy mothers, according to a study presented at the 69th Annual Scientific Meeting of the American College of Gastroenterology.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced the publication of new data in the journal Nature Biotechnology by Alnylam scientists and collaborators from Tekmira Pharmaceuticals Corporation, AlCana Technologies, Inc., and The University of British Columbia (UBC). The new study employed a rational design approach for the discovery of novel lipids that can be incorporated into lipid nanoparticles (LNPs) for systemic delivery of RNAi therapeutics.
› Verified 7 days ago
Mailing Address | Practice Location Address |
---|---|
John Fasig Iii, MD 5301 Virginia Way, Suite 300, Brentwood, TN 37027-7541 Ph: (615) 221-4474 | John Fasig Iii, MD 5301 Virginia Way, Suite 300, Brentwood, TN 37027-7541 Ph: (615) 221-4474 |
News Archive
Today's early morning highlights from the major news organizations include news on congressional package to payroll taxes and stop a Medicare payment cut and analysis of President Barack Obama's budget.
Researchers at Moffitt Cancer Center in Tampa, Fla., have found - contrary to previous studies linking inferior outcomes in patients with gastrointestinal malignancies to higher body mass index (BMI) - that in their study of BMI and negative outcomes, there was no such link. They concluded that BMI was not associated with either surgical complications or esophageal cancer patient survival.
Vertex Pharmaceuticals Incorporated today announced plans to enroll an additional treatment arm as part of its ongoing Phase 2 clinical trial evaluating 12-week regimens of Vertex's lead investigational hepatitis C virus (HCV) protease inhibitor, telaprevir, in combination with its lead investigational HCV polymerase inhibitor, VX-222.
Infants born to women with Inflammatory Bowel Disease (IBD) are no more likely to develop congenital malformations than infants born to healthy mothers, according to a study presented at the 69th Annual Scientific Meeting of the American College of Gastroenterology.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced the publication of new data in the journal Nature Biotechnology by Alnylam scientists and collaborators from Tekmira Pharmaceuticals Corporation, AlCana Technologies, Inc., and The University of British Columbia (UBC). The new study employed a rational design approach for the discovery of novel lipids that can be incorporated into lipid nanoparticles (LNPs) for systemic delivery of RNAi therapeutics.
› Verified 7 days ago
Kathy Bruner, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 5301 Virginia Way, Suite 300, Brentwood, TN 37027 Phone: 615-221-4474 Fax: 615-234-3774 | |
Kenneth S Piech, M.D. Pathology Medicare: Medicare Enrolled Practice Location: 5301 Virginia Way, Ste 300, Brentwood, TN 37027 Phone: 615-221-4474 Fax: 615-234-3774 | |
Roy W. Kirchberg Jr., M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 5301 Virginia Way, Ste 300, Brentwood, TN 37027 Phone: 615-221-4474 Fax: 615-234-3774 | |
Dr. Lori D Emerson, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 5301 Virginia Way, Suite 300, Brentwood, TN 37027 Phone: 615-695-4977 | |
Ben W Davis, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 5301 Virginia Way Ste 300, Brentwood, TN 37027 Phone: 615-221-4474 Fax: 615-234-3774 | |
Randall L Woodford, MD Pathology Medicare: Medicare Enrolled Practice Location: 5301 Virginia Way, 300, Brentwood, TN 37027 Phone: 615-221-4474 Fax: 615-234-3774 | |
Dr. Soheila Yadrandji, MD Pathology Medicare: Medicare Enrolled Practice Location: 5301 Virginia Way, Suite 300, Brentwood, TN 37027 Phone: 615-221-4474 Fax: 615-234-3774 |